Comparison of Intravenous with Oral Busulfan in Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Regimens for Pediatric Acute Leukemia  by Kato, Motohiro et al.
Biol Blood Marrow Transplant 19 (2013) 1690e1694American Society for Blood
ASBMT
and Marrow TransplantationComparison of Intravenous with Oral Busulfan in Allogeneic
Hematopoietic Stem Cell Transplantation with
Myeloablative Conditioning Regimens for Pediatric Acute
Leukemia
Motohiro Kato 1,2,3,*, Yoshiyuki Takahashi 4, Daisuke Tomizawa 5,
Yasuhiro Okamoto 6, Jiro Inagaki 7, Katsuyoshi Koh 3, Atsushi Ogawa 8,
Keiko Okada 9, Yuko Cho 10, Junko Takita 1,2, Hiroaki Goto 11,
Hisashi Sakamaki 12, Hiromasa Yabe 13, Keisei Kawa 14, Ritsuro Suzuki 15,
Kazuko Kudo 16, Koji Kato 17
1Department of Cell Therapy and Transplantation Medicine, The University of Tokyo, Tokyo, Japan
2Department of Pediatrics, The University of Tokyo, Tokyo, Japan
3Department of Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan
4Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
5Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan
6Department of Pediatrics, Kagoshima University, Kagoshima, Japan
7Department of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan
8Department of Pediatrics, Niigata Cancer Center Hospital, Niigata, Japan
9Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan
10Department of Pediatrics, Hokkaido University Hospital, Sappro, Japan
11Division of Hemato-oncology/Regenerative Medicine, Kanagawa Children’s Medical Center, Yokohama, Japan
12Department of Hematology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
13Department of Cell Transplantation and Regenerative Medicine, Tokai University, Isehara, Japan
14 Japanese Red Cross Kinki Block Blood Center, Osaka, Japan
15Department of HSCT Data Management and Biostatistics, Nagoya University, Nagoya, Japan
16Division of Hematology and Oncology, Shizuoka Children’s Hospital, Shizuoka, Japan
17Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, JapanArticle history:
Received 23 July 2013
Accepted 17 September 2013
Key Words:
Acute leukemia
Children
BusulfanFinancial disclosure: See Acknowl
* Correspondence and reprint
Department of Pediatrics, Univers
Tokyo, Japan.
E-mail address: katom-tky@um
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Recent reports revealed that intravenous (iv) busulfan (BU) may not only reduce early nonrelapse mortality
(NRM) but also improve overall survival (OS) probability in adults. Therefore, we retrospectively compared
outcomes for 460 childrenwith acute leukemia who underwent hematopoietic stem cell transplantation with
either iv-BU (n ¼ 198) or oral busulfan (oral-BU) (n ¼ 262) myeloablative conditioning. OS at 3 years was
53.4%  3.7% with iv-BU and 55.1%  3.1% with oral-BU; the difference was not statistically signiﬁcant
(P ¼ .77). OS at 3 years in 241 acute lymphoblastic leukemia and 219 acute myeloid leukemia patients was
56.4%  5.5% with iv-BU and 54.6%  4.1 with oral-BU (P ¼ .51) and 51.0%  5.0% with iv-BU and 55.8%  4.8%
with oral-BU (P ¼ .83), respectively. Cumulative incidence of relapse at 3 years with iv-BU was similar to that
with oral-BU (39.0%  3.6% and 36.4%  3.1%, respectively; P ¼ .67). Cumulative incidence of NRM at 3 years
was 16.6%  2.7% with iv-BU and 18.3%  2.5% with oral-BU (P ¼ .51). Furthermore, multivariate analysis
showed no signiﬁcant survival advantage with iv-BU. In conclusion, iv-BU failed to show a signiﬁcant survival
advantage in children with acute leukemia.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Busulfan (BU) is an alkylating agent that plays an impor-
tant role in myeloablative preconditioning regimens in
hematopoietic stem cell transplantation (HSCT) for patients
with malignant diseases [1]. Although it has a potent anti-
leukemic effect and excellent central nervous system pene-
tration, wide inter- and intrapatient variability in absorption
and metabolism has been observed with oral BU (oral-BU)
[2]. However, its therapeutic potential has been com-
promised with unpredictable adverse events becauseedgments on page 1693.
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13.09.012overdosing leads to severe toxicity, and underdosing can
potentially cause a relapse [3,4] or graft failure [5].
In children, BU is an important substitute for total body
irradiation (TBI) [6], which is often associated with a higher
incidence of late complications [7]; however, the range of
heterogeneity in bioavailability with oral-BU is problematic.
Blood concentrations and clearance may vary up to 6-fold
among children receiving oral-BU [8,9], and age-dependent
BU metabolism results in further complications. Therefore,
therapeutic drug monitoring (TDM) of oral-BU has been
considered an essential practice in children undergoing stem
cell transplantation [10,11].
Intravenous BU (iv-BU) has recently replaced oral-BU
because iv-BU avoids oral-BU’s variable bioavailability.
Furthermore, iv-BU showed less hepatic toxicity by avoid-
ing the hepatic ﬁrst-pass effect of oral-BU [12]. Previous
reports revealed that the use of iv-BU reduced earlyTransplantation.
Table 1
Patients’ Characteristics
Characteristics Total,
n
iv-BU,
n (%)
Oral-BU,
n (%)
P
Value
All patients 460 198 262
Age at HSCT .23
<1 yr 83 34 49
1 to 10 yrs 278 128 150
>10 yrs 99 36 63
Gender .19
Male 237 95 142
Female 223 103 120
Year of HSCT <.001
2000 to 2003 159 4 155
2004 to 2007 155 52 103
2008 to 2010 146 142 4
Underlying disease .01
ALL, total 241 90 151
B lineage 198 76 122
T lineage 22 9 13
Not determined 21 5 16
AML, total 219 108 111
M0 7 4 3
M1 31 11 20
M2 37 18 19
M3 3 2 1
M4 31 12 19
M5 46 24 22
M6 6 3 3
M7 48 28 20
Not determined 7 5 2
Disease status .29
CR1 205 85 120
CR2 74 28 46
>CR2 and non-CR 179 85 94
Unknown 2 0 2
Prior HSCT
No 343 147 196
Yes 117 51 66
Donor type <.001
Related donor 189 71 118
BM 131 54 77
PB 58 17 41
Unrelated donor BM 67 43 24
Cord blood 199 83 116
Unknown 5 1 4
Usage in preconditioning
regimens
CY 219 87 132 .19
VP16 150 59 91 .27
L-PAM 226 101 125 .51
ALL indicates acute myeloid leukemia; AML, acute myeloid leukemia; iv-BU,
intravenous busulfan; oral-BU, oral busulfan; CR, complete remission; HSCT,
hematopoietic stem cell transplantation; BM, bone marrow; PB, peripheral
blood; CY, cyclophosphamide; VP16, etoposide; L-PAM, melphalan.
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Figure 1. Overall survival probability of transplantation. Overall survival probability ar
and (C) in patients with AML.
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syndrome (SOS) [13,14], and decreased early nonrelapse
mortality (NRM) [13-15]. Some reports demonstrated that
iv-BU may provide better overall survival (OS) in adults
with malignant diseases [14-17].
Although several reports have been published on children
with iv-BU [18-20], the number of patients included was
small, and the reports mainly focused on acute toxicity or
early clinical outcome because of a short follow-up period.
Therefore, the role of iv-BU in HSCT for children with acute
leukemia is yet to be determined.
In this study, to compare the clinical outcome of HSCT
with iv-BU and oral-BU, we performed a retrospective anal-
ysis in 460 children who underwent myeloablative condi-
tioning regimens including BU after allogeneic
transplantation for acute leukemia.
METHODS
This study was approved by the institutional ethics committee of
Saitama Children’s Medical Center. A total 460 patients were analyzed based
on the data reported in the Japan Society for Hematopoietic Cell Trans-
plantation registry [21] (Table 1). The patients were selected based on the
following criteria: (1) patients diagnosed with either acute lymphoblastic
leukemia (ALL) or acute myeloid leukemia (AML); (2) age 15 years or
younger when receiving HSCT; (3) BU-based myeloablative (more than
8 mg/kg) preconditioning regimens; and (4) HSCT performed between 2000
and 2010.
The OS probability was calculated using Kaplan-Meier estimates.
Cumulative incidence curves were used in competing risks settings to
calculate the probability of engraftment, graft-versus-host disease, and
NRM. Univariate analyses of OS were performed using the log-rank test, and
Gray’s test was used for group comparisons of cumulative incidences.
Multivariate analysis was performed using the Cox proportional hazard
regression model, and the variables considered were patient’s age, under-
lying diseases (ALL or AML), disease status (low risk: ﬁrst complete remis-
sion [CR] or second CR, or high risk: nonremission or later than second CR),
prior HSCT, donor type, and form of BU. All statistical analyses were per-
formed using R software 2.13.0 (The R Foundation for Statistical Computing,
Vienna, Austria). A 2-sided P value of less than .05 was considered to be
statistically signiﬁcant.
RESULTS
The patients’ characteristics are listed in Table 1. The
median age at HSCT was 4 years (range, 0 to 15 years). Of the
460 HSCT patients, 198 used iv-BU and 262 used oral-BU. The
iv-BU replaced oral-BU in most of the cases after the iv-BU
approval in Japan in 2006 (Table 1). The median follow-up
period was 1828 days (range, 85 to 4619 days) after HSCT
in all the surviving patients and 1185 days (range, 100 to
3759 days) after HSCT in the iv-BU patients.0 1200
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Table 2
Multivariate Analysis of the Risk Factors for Overall Mortality
Characteristics No. of
Patients
Overall Mortality
Hazard Ratio
(95% CI)
P
Value
Patient age at HSCT
<1 yr 83 1
1 to 9 yrs 278 1.18 (.76 to 1.86) .45
>10 yrs 99 1.39 (.83 to 2.33) .21
Underlying disease
ALL 241 1
AML 219 1.00 (.75 to 1.34) .98
Disease status
Low risk (CR1 and CR2) 279 1
High risk (>CR2 and nonCR) 179 3.92 (2.86 to 5.39) <.0001
Prior HSCT
No 343 1
Yes 117 1.47 (1.06 to 2.03) .02
Donor type
Related donor 189 1
Unrelated donor (bone marrow) 67 1.09 (.72 to 1.64) .68
Cord blood 199 1.22 (.90 to 1.66) .19
Form of busulfan
Oral 262 1
Intravenous 198 .80 (.60 to 1.06) .12
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia;
CI, conﬁdence interval; CR, complete remission; HSCT, hematopoietic stem
cell transplantation.
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3 years after HSCT was 54.6% 2.4%, whereas the cumulative
incidence of relapse and NRM were 37.5%  2.3% and
17.6%  1.8%, respectively.
Although OS with iv-BU and oral-BU at day 100 after
HSCT was 72.5%  3.2% and 66.9%  2.9%, respectively, OS
at 3 years after HSCT was similar (iv-BU, 53.4%  3.7%;
oral-BU, 55.1%  3.1%), and the log-rank test for OS did not
show a statistically signiﬁcant difference (P ¼ .77)
(Figure 1A). The result was concordant even when the
analysis was limited to patients with ALL or AML. OS at
3 years for patients with ALL using iv-BU (n ¼ 90) and oral-
BU (n ¼ 151) was 56.4%  5.5% and 54.6%  4.1%, respec-
tively (P ¼ .51) (Figure 1B). OS at 3 years for patients with
AML using iv-BU (n ¼ 108) and oral-BU (n ¼ 111) was
51.0%  5.0% and 55.8%  4.8%, respectively (P ¼ .83)
(Figure 1C).
The similarity of OSwas reproduced evenwith the limited
cohort of 247 patients who received HSCT after the ﬁrst CR or
second CR without prior HSCT. OS at 3 years was
78.3%  4.2% for iv-BU patients (n ¼ 98) and 78.7%  3.4% for0 500 1000 1500
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(C) in patients with AML.oral-BU patients (n ¼ 149) and the difference was not
statistically signiﬁcant (P ¼ .66).
In addition, the hazard ratio of overall mortality between
iv-BU and oral-BU was not statistically signiﬁcant based on
the multivariate analysis (Table 2).
The cumulative incidence curve of relapse after 3 years of
iv-BU (39.0% 3.6%) was superimposed on the oral-BU curve
(36.4%  3.1%) (Figure 2A). The difference did not show
statistical signiﬁcance after limiting the analyses to each
disease. Relapse incidence at 3 years was 41.7%  5.5% with
iv-BU and 39.1%  4.0% with oral-BU in the ALL cohort (P ¼
.56) (Figure 2B), and 37.0%  4.8% with iv-BU and
33.6%  4.7% with oral-BU in the AML cohort (P ¼ .70)
(Figure 2C).
The cumulative incidence of NRM at 100 days after HSCT
was 6.8% 1.8%with iv-BU and 8.3% 1.7%with oral-BU, and
NRM at 3 years after HSCT was 16.6%  2.7% with iv-BU and
18.3%  2.5% with oral-BU (P ¼ .51) (Figure 3A). The SOS
occurrence was evaluable in 173 patients. Twenty-seven
(30.3%) of 89 patients using iv-BU and 23 (27.4%) of 84
patients using oral-BU had SOS (P ¼ .74). One patient using
iv-BU and 4 patients using oral-BU succumbed to SOS. No
signiﬁcant difference in the causes of death was noted
between the iv-BU and oral-BU groups.
The iv-BU group showed a tendency toward higher
engraftment probability at day 60 (96.0%  1.5%) compared
with the oral-BU group (89.3% 2.0%), but the differencewas
not statistically signiﬁcant (P ¼ .22) (Figure 3B). The cumu-
lative incidence of acute graft-versus-host disease (grade II to
IV) at day 100 was similar (iv-BU, 37.7%  3.5%; oral-BU,
35.4%  3.0%; P ¼ .98).DISCUSSION
Busulfan is widely used as an alternative myeloablative
agent to TBI. Although previous randomized studies and
a meta-analysis comparing BU with TBI revealed that TBI-
based regimens were at least as good for survival and
disease-free survival [22], it should be noted that majority of
BU in these studies was oral-BU, and recent reports showed
that targeted BU with TDM or iv-BU could improve HSCT
outcome [10,11,14-17,23]. However, this study included the
largest number of children to date and demonstrated that the
advantage of iv-BU on survival probability was not signiﬁ-
cant. The result was reproduced in subgroups, such as
patients with ALL, patients with AML, and patients who
received iv-BU at ﬁrst or second CR without prior HSCT.C
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beneﬁt with iv-BU.
Our results regarding the iv-BU usage were discordant
with the previous studies in adults. Although the reason is
unclear, a possible explanation could be that the optimal
dosing was already achieved in most patients, even those on
oral-BU. In children, TDM of oral-BU has been considered an
essential practice [10,11]. Therefore, the administration dose
in oral-BU patients was usually determined based on the
results of the test dose administration result and it was also
adjusted according to TDM result.
Dosing schedule based on body weight using iv-BU
provided adequate therapeutic targeting in children [24]. In
our study, iv-BU failed to show superior outcomes compared
with oral-BU, but it could provide a comparable survival
outcome with a reduced requirement for TDM.
Concordant with previous studies, short-term NRM and
OS in our study seemed to be superior in the iv-BU group
compared with the oral-BU group, although it was caused by
improvement of support therapy. Therefore, iv-BU may be
advantageous for patients with high risk for treatment-
related mortality, such as poor performance status, uncon-
trolled infectious diseases, or organ dysfunction.
This retrospective study, using the registry data, has some
limitations. For example, the selection of iv-BU or oral-BU
was strongly associated with the transplantation period,
which may have introduced bias. Further prospective studies
are required to establish an optimal allogeneic HSCT treat-
ment strategy for children with acute leukemia.
In conclusion, our study provides valuable information on
the role of iv-BU in myeloablative HSCT for pediatric acute
leukemia. In children, iv-BU failed to improve the survival
outcome of acute leukemia.ACKNOWLEDGMENTS
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